Rising Global Metabolic Disease Burden Driving Strong Structural Demand for GLP-1 Therapies Growth of the GLP-1 receptor agonist market is mainly attributed to the rising prevalence of Type 2 diabetes and obesity on a global scale
Health Canada has issued parallel advisories on unauthorized injectable peptide products, and no AOD-9604 preparation is authorized for compounding in Canada either
By purchasing from Alixa Pharma, you acknowledge and agree that all products are supplied strictly for laboratory research purposes only
In people with earlier stages of CKD, these models can help identify those who may have the greatest benefit from early health behaviour and drug therapy combination interventions that could change the trajectory of their fall in eGFR over time (Figure 5)
The mechanisms by which rotenone upregulates -synuclein and causes its aggregation, are not well understood
Here is the reality: The regulatory situation is complicated, evolving, and frankly somewhat messy right now